Access to antiviral therapy for chronic hepatitis B during COVID-19
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
Associação Médica Brasileira
Citação
REVISTA DA ASSOCIAçãO MéDICA BRASILEIRA, v.68, n.11, p.1509-1513, 2022
Resumo
Abstract OBJECTIVE: Hepatitis B is an important public health concern. Currently, the COVID-19 pandemic is a major challenge for health systems, and the access to pharmacologic and non-pharmacologic treatment of chronic diseases, such as hepatitis B, may have been affected due to the contingency measures. This study aimed to evaluate the access to antiviral therapy during the ongoing pandemic. METHODS: This was a descriptive analysis of the access to treatment for chronic hepatitis B at a tertiary-level university hospital in São Paulo, integrated with the Brazilian health system. The study was conducted from April to December 2020. RESULTS: Access to antiviral therapy for 225 patients was assessed. The majority of the population was male (59%). The main type of service was the Programa Medicamento em Casa (Home Medication Delivery Program), which was availed by 144 (64%) patients. Women had poorer access to antiviral therapy (56%, p<0.05), and patients registered in the HMDP (68%, p<0.05) had better access. The age group of >48 years represented 70% of the group without access to antiviral therapy. Twenty-two pharmaceutical appointments were conducted through phone calls with patients without access to antiviral therapy. CONCLUSION: This study contributes to the rationalization of efforts in a public health crisis through the identification of groups with the highest risk of poor access to antiviral therapy and the demonstration of the benefits of a medication delivery system.
Palavras-chave
Hepatitis B, Antiviral agents, COVID-19, Public health
Referências
- Abreu RM, 2019, ANTIVIR THER, V24, P567, DOI 10.3851/IMP3338
- Abreu RM, 2016, INFECT DIS THER, V5, P53, DOI 10.1007/s40121-015-0101-y
- Aghemo A, 2020, DIGEST LIVER DIS, V52, P937, DOI 10.1016/j.dld.2020.07.008
- [Anonymous], 2020, LANCET GASTROENTEROL, V5, P789, DOI 10.1016/S2468-1253(20)30237-5
- [Anonymous], 2017, GLOB HEP REP 2017
- Aquino Estela M. L., 2020, Ciênc. saúde coletiva, V25, P2423
- Awucha NE, 2020, AM J TROP MED HYG, V103, P1630, DOI 10.4269/ajtmh.20-0838
- Cadogan CA, 2021, RES SOC ADMIN PHARM, V17, P2032, DOI 10.1016/j.sapharm.2020.03.015
- Coroiu A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239795
- de Fraga RS, 2020, J GASTROENTEROL, V55, P496, DOI 10.1007/s00535-020-01680-0
- Ford N, 2018, HEPATOL COMMUN, V2, P1160, DOI 10.1002/hep4.1247
- Ha NB, 2016, J CLIN GASTROENTEROL, V50, P169, DOI 10.1097/MCG.0000000000000345
- Kretchy IA, 2021, RES SOC ADMIN PHARM, V17, P2023, DOI 10.1016/j.sapharm.2020.04.007
- Levorato Cleice Daiana, 2014, Ciênc. saúde coletiva, V19, P1263, DOI 10.1590/1413-81232014194.01242013
- Lieveld FI, 2013, ANN HEPATOL, V12, P380, DOI 10.1016/S1665-2681(19)31000-2
- Zheng SQ, 2021, RES SOC ADMIN PHARM, V17, P1819, DOI 10.1016/j.sapharm.2020.03.012
- Casos confirmados notificados no sistema de informação de agravos de notificação - São Paulo
- 2016, Protocolo Clinico e Diretrizes Terapeutica para Hepatitie C e Coinfeccoes. Brasilia 2011